These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32067336)

  • 1. Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation.
    Tanase T
    Pharm Stat; 2020 Mar; 19(2):126-136. PubMed ID: 32067336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
    Nomura S; Hirakawa A; Hamada C
    J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Power and sample size for randomized phase III survival trials under the Weibull model.
    Wu J
    J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
    Lakdawalla DN; Shafrin J; Hou N; Peneva D; Vine S; Park J; Zhang J; Brookmeyer R; Figlin RA
    Value Health; 2017; 20(7):866-875. PubMed ID: 28712615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of cancer trials based on progression-free survival with intermittent assessment.
    Zeng L; Cook RJ; Lee KA
    Stat Med; 2018 May; 37(12):1947-1959. PubMed ID: 29582452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Kearney M; Stevens JW; Benedict A; Bharmal M
    Pharmacoeconomics; 2019 Dec; 37(12):1537-1551. PubMed ID: 31555968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
    Denne JS; Stone AM; Bailey-Iacona R; Chen TT
    J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.
    Castonguay V; Wilson MK; Diaz-Padilla I; Wang L; Oza AM
    Cancer; 2015 Feb; 121(3):413-22. PubMed ID: 25278038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.
    Liang F; Wu Z; Mo M; Zhou C; Shen J; Wang Z; Zheng Y
    Eur J Cancer; 2019 Nov; 121():19-28. PubMed ID: 31526874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategic view of randomized trial design in low-incidence paediatric cancer.
    Sposto R; Stram DO
    Stat Med; 1999 May; 18(10):1183-97. PubMed ID: 10363339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of treatment effect under non-proportional hazards and conditionally independent censoring.
    Boyd AP; Kittelson JM; Gillen DL
    Stat Med; 2012 Dec; 31(28):3504-15. PubMed ID: 22763957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Dodd LE; Korn EL; Freidlin B; Jaffe CC; Rubinstein LV; Dancey J; Mooney MM
    J Clin Oncol; 2008 Aug; 26(22):3791-6. PubMed ID: 18669467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.
    Tanase T; Hamada C; Yoshino T; Ohtsu A
    Anticancer Res; 2017 Oct; 37(10):5851-5855. PubMed ID: 28982911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.
    Tan SB; Chung YF; Tai BC; Cheung YB; Machin D
    Control Clin Trials; 2003 Apr; 24(2):110-21. PubMed ID: 12689733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.